Jürgen Rockstroh, MD, is a Professor of Medicine and Head of the HIV Outpatient Clinic at the University of Bonn in Germany. He earned a Doctor of Medicine degree from the Rheinische Friedrich-Wilhelms University of Bonn and completed his residency in the Department of Medicine also at the University of Bonn. His department treats the world’s largest cohort of HIV-infected hemophiliacs. In addition to his clinical practice, Dr. Rockstroh is involved in HIV research on antiretroviral therapy, including new drug classes; the course of HIV disease in haemophiliacs; and HIV and hepatitis co-infection. He has been an investigator in multiple clinical trials of antiretroviral agents and treatments for HIV and hepatitis co-infection. From 2007-2011 he was elected as the president of the German AIDS Society. Since 2009, he is also a member of the executive committee of the European AIDS Clinical Society (EACS), and since 2011, a member of the governing council of the International AIDS Society. He also was the chair of the National German AIDS Advisory Panel from 2011-2017 and the EACS coinfection guidelines from 2008-2017. In 2015 Professor Rockstroh was elected chair of HIV in Europe (in 2019 renamed as EuroTEST) and in 2019, president for EACS.
At the completion of this educational session, learners will:
- Know the current epidemiology of the COVID-19 epidemic in Europe.
- Be aware of testing and prevention strategies as well as clinical management and therapeutic options for COVID-19.
- Understand the risk of COVID-19 infection in HIV-infected individuals.
This CME activity has approved for AMA PRA Category 1 Credit™
for April 8, 2020 as a live activity. This activity will also be available as an enduring activity from April 9, 2020, through April 7, 2023.
The target audience is all physicians, NPs and PAs involved or interested in HIV education.
This online video and post-activity evaluation are one hour in length.
After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz.
You must achieve at least 70% correct to receive your CME certificate.
If successful, you will be provided instructions to print your CME certificate at the completion of this activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Policies and standards of the Medical Society of the State of New York and the Accreditation Council for Continuing Medical Education require that speakers and planners for continuing medical education activities disclose any relevant financial relationships they may have with commercial interests whose products, devices, or services may be discussed in the content of a CME activity.
Dr. William Valenti (Course Director) had no relevant financial relationships to disclose.
Dr. Jürgen Rockstroh (Presenter) has had the following personal financial relationships in the past 12 months with manufacturers of the products or services that may be presented in this CME activity: honoraria for consulting or speaking at educational events from Gilead, Janssen, Merck, Theratechnologies, and ViiV. Dr. Rockstroh will support his presentation and clinical recommendations with the best available evidence from the medical literature and will submit his slides in advance for adequate peer review.
This PRN CME activity is funded in part by unrestricted educational grants from:
Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; and Merck & Co.